Vulvovaginal Candidiasis (VVC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Vulvovaginal Candidiasis (VVC) Market Outlook
Thelansis’s “Vulvovaginal Candidiasis
(VVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Vulvovaginal Candidiasis (VVC)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Vulvovaginal
Candidiasis (VVC) Overview
Vulvovaginal
Candidiasis (VVC) occurs when Candida species superficially penetrate the
mucosal lining of the vagina and cause an inflammatory response. The dominant
inflammatory cells are typically polymorphonuclear cells and macrophages.
Patients may present with discharge, which is usually thick and adherent,
excoriations, external dysuria, vaginal itching, vaginal burning, dyspareunia,
or swelling. Risk factors for acute candidal vulvovaginitis include estrogen
use, elevated endogenous estrogens, diabetes mellitus, immunosuppression, and
broad-spectrum antibiotic use. Although candidal vulvovaginitis is more common
in sexually active women, there is no evidence that candidal infection is
sexually transmitted. Patients with recurrent candidal vulvovaginitis have
predisposing genetic factors that cause them to be susceptible to recurrent
fungal infections. These factors may also predispose to hypersensitivity to
Candida. The most common responsible pathogen is C. albicans (in about 90% of
cases), with most of the remaining cases caused by Candida glabrata.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment